00000cab a22000003a 4500 UP-99796217609180395 Buklod 20231007234045.0 m |o d | ta 100305s xx d | ||r ||||| || DENGII eng Guccione, S. Molecular imaging and therapy directed at the neovasculature in pathologies. pp. 50-56 This paper discussed the impact of molecular imaging on clinical and preclinical medicine. Potential problems of delivering the effective therapeutic dose and the properties that can help contribute to the drug efficacy were presented. The rationale for the design of new antiangiogenic agents that can be used for imaging and therapy was presented. Finally, results from imaging and targeted nanoparticle-based therapies were presented. In vivo imaging of angiogenic tumors using anti-αvβ3-targeted polymerized vesicles composed of the murine antibody LM609 attached to nanoparticles labeled with the MR contrast agent gadolinium in the V2 carcinoma model in rabbits. MRI studies using this targeted contrast agent revealed large areas of αvβ3 integrin expression in tumor-associated vasculature that conventional MRIs failed to show. By modification of the nanoparticles this imaging agent was used as an antiangiogenic gene delivery system. spl alpha//sub v//spl beta//sub 3/ integrin expression. MRI. V2 carcinoma. Anti-/spl alpha//sub v//spl beta//sub 3/-targeted polymerized vesicles. Antiangiogenic agents. Antiangiogenic gene delivery system. Clinical medicine. Drug efficacy. Gadolinium. In vivo angiogenic tumor imaging. Molecular imaging. Murine antibody LM609. Nanoparticle-based therapies. Neovasculature. Preclinical medicine. Rabbits. Targeted contrast agent. Therapy. Tumor-associated vasculature. IEEE Engineering in medicine and biology magazine 23, 5 (2004). FO UPD DENG-II Article